Business
Grant of AESOP Options and PDMR Dealing
Grant of AESOP Options and PDMR Dealing.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n Arecor Therapeutics plc\n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n \n Grant of AESOP Options, PDMR Dealing\n \n \n \n \n \n \n \n \n Cambridge, UK, \n 17\n November 2022:\n \n Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives\n ,\n \n announces that\n on 16 November 2022, it granted a total of 323,500 options under the Company's All Employee Share Ownership Plan (\"AESOP Options\") over new ordinary shares of 0.1 pence each in the Company (\"Ordinary Shares\").\n \n \n The AESOP Options vest after 36 months and are exercisable at £2.45 per share being the closing market price of an Ordinary Share on the day preceding the date of grant. The AESOP Options are subject to continuous employment, vest in accordance with the vesting term notified to the option holder and are exercisable until the tenth anniversary of the date of grant, after which date the option will lapse.\n \n \n The following 159,000 AESOP Options were granted to persons discharging managerial responsibilities (\"PDMR\"):\n \n \n \n \n \n \n \n PDMR\n \n \n \n \n \n \n Position/status\n \n \n \n \n \n \n Number of AESOP options granted on 16 November 2022\n \n \n \n \n \n \n Total number of AESOP options held\n \n \n \n \n \n \n \n Shafiq Choudhary\n \n \n \n \n Managing Director, Tetris Pharma\n \n \n \n \n 40,000\n \n \n \n \n 40,000\n \n \n \n \n \n \n David Gerring\n \n \n \n \n VP Development\n \n \n \n \n 40,000\n \n \n \n \n 70,000\n \n \n \n \n \n \n Sarah Howell\n \n \n \n \n Chief Executive Officer\n \n \n \n \n 33,000\n \n \n \n \n 133,000\n \n \n \n \n \n \n Jan Jezek\n \n \n \n \n Chief Scientific Officer\n \n \n \n \n 13,000\n \n \n \n \n 53,000\n \n \n \n \n \n \n Fiona Lawrence\n \n \n \n \n VP Clinical Development and Reg. Affairs\n \n \n \n \n 10,000\n \n \n \n \n 40,000\n \n \n \n \n \n \n Susan Lowther\n \n \n \n \n Chief Financial Officer\n \n \n \n \n 23,000\n \n \n \n \n 93,000\n \n \n \n \n \n \n The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.\n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n Arecor Therapeutics plc\n \n \n \n \n \n \n \n \n \n \n \n \n www.arecor.com\n \n \n \n \n \n...